Deal Watch: Alnylam/Dicerna Pact Addresses IP Questions Around Primary Hyperoxaluria Programs
The two RNAi firms cross-license IP from their PH programs, while also partnering on a rare liver disease candidate. GSK invests $250m in Vir and will help to advance its antibody candidates for COVID-19.
You may also be interested in...
The French firm’s vorasidenib, obtained via a 2020 deal with Agios, has met the primary endpoint in a pivotal glioma trial, according to interim data, validating its strategic focus on the oncology space.
The privately held company expects five US FDA approvals by 2026 and will focus on big-ticket targets like immune checkpoints and cell therapies, CEO David K. Lee told Scrip.
The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.